Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.51 |
| ▸ | CDK1 | P06493 | 18/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 14/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 14/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17186345 | 0.99 | CDK2 (0.50) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL17186437 | 0.98 | CDK2 (0.48) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL17186334 | 0.96 | CDK2 (0.46) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL18605794 | 0.95 | CDK2 (0.46) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL17186421 | 0.94 | CDK2 (0.43) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL18605843 | 0.93 | CDK2 (0.42) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL4156905 | 0.88 | CDK2 (0.49) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL18605622 | 0.86 | CDK2 (0.48) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL6270961 | 0.86 | CDK2 (0.48) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL6273296 | 0.82 | MPO (0.46) | CDK2CDK1CCNB1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | CDK2 866/4885CDK1 592/4885CCNB1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.